Pharmaceutical technology company Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) on Wednesday announced its financial consolidated results for the six months ended 30 June 2025.
Innocan said that this period delivered a positive swing in its operating profitability and continued strengthening of its balance sheet.
Revenues decreased by 4% in the first half of 2025 to USD14.8m, from USD15.4m in the first half of 2024, attributed to uncertainty in the markets as a result of global trade tariffs.
Gross profit was down 4.9% to USD13.3m, compared to USD14.m in the first half of last year, while operating profit increased by 130% to USD0.885m, from an operating loss of USD0.680m a year earlier.
Wolters Kluwer launches UpToDate Expert AI to deliver trusted GenAI clinical decision support
Abbott announces quarterly common dividend
CVS Health declares unchanged quarterly dividend
ALK partners with GenSci to expand allergy immunotherapy market in China
Innocan Pharma reports 'positive swing' in operating profitability for first half of 2025
Wolters Kluwer boosts medical research efficiency with Ovid AI summarisation
European Commission approves Gilead's twice-yearly HIV prevention injection Yeytuo
Essa Pharma clarifies Nasdaq due bill trading period for cash distribution
Advanz Pharma and Alvotech secure European approval for aflibercept biosimilar Mynzepli
Heron Therapeutics announces tax benefits preservation plan adoption
Essa Pharma sets ex-dividend date and due bill trading for USD80m capital return
BioDlink's bevacizumab injection secures Colombia and Pakistan marketing authorisation
GSK to receive USD370m and future royalties in CureVac/BioNTech settlement